Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29738536 | 1.00 | PNMT (0.32) | PNMTTAAR1IDO1MAOB | |
| SCHEMBL17062073 | 0.87 | IDO1 (0.33) | PNMTTAAR1IDO1 | |
| SCHEMBL15814084 | 0.86 | ACHE (0.37) | PNMTTAAR1MAOB | |
| SCHEMBL29738548 | 0.86 | ACHE (0.37) | PNMTTAAR1MAOB | |
| SCHEMBL1239272 | 0.84 | CES2 (0.38) | MAOB | |
| SCHEMBL10835146 | 0.83 | PNMT (0.31) | PNMTTAAR1 | |
| SCHEMBL17069252 | 0.81 | HTR2A (0.33) | PNMTTAAR1MAOB | |
| SCHEMBL23024944 | 0.76 | MAOB (0.39) | IDO1MAOB | |
| SCHEMBL31372011 | 0.74 | TRPV4 (0.41) | — | |
| SCHEMBL4524759 | 0.73 | MAPT (0.42) | PNMTTAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055016-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4055016-A1 | GPR52 MODULATOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-09-14 | — | — | EP | disclosed |
| CN-114650992-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-105793238-B | Substituted benzamides and methods of use thereof | 基因泰克公司 | 2019-12-24 | — | — | CN | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| CN-105793238-A | Substituted benzamides and methods of use thereof | 基因泰克公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR4 | PNMT 3923/4885TAAR1 339/4885IDO1 2753/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | PNMT 1911/4885TAAR1 2635/4885IDO1 2403/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | PNMT 2378/4885TAAR1 3479/4885IDO1 2828/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | PNMT 1402/4885TAAR1 1902/4885IDO1 2555/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | PNMT 1911/4885TAAR1 2635/4885IDO1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.